Figure 5.

Results of nestin and CD44 immunodetection in bone marrow of different irradiated mouse groups by flow cytometry and immunofluorescence in the short term (D62) (A,B) and comparison of nestin and CD44 immunodetection in bone marrow between groups treated with hIDPSC and saline in the short term (D62) and long term (D182), respectively. Results show that the exposure to TBI reduced the number of nestin- (A) and CD44-positive cells (B) 48 h after the irradiation in relation to non-irradiated mice (*). However, the treatment with hIDPSCs increased the number of nestin- (*) (A) and CD44-positive cells (**) (B) in relation to the irradiated. These results were also confirmed by immunofluorescence (A,B). Results show statistical difference in the number of nestin-positive cells between the hIDPSC-treated group and those treated with saline (*) (A). In contrast, the saline group showed a statistical increase (*) in the number of CD44-positive in relation to the irradiated (B). The graph (C) is the comparison between irradiated + hIDPSC-treated group and irradiated + saline group in the short term (D62) and irradiated + hIDPSC-treated group and irradiated + saline group in the long term (D182). The results showed the statistical difference between the group treated with hIDPSC and saline (*) in percentage of nestin-positive in the short term (D62) (A) and after 6 months or D182 (long-term) did not show a statistical difference (C). In addition, the percentage of CD44-positive did not show a statistical difference between group treated with hIDPSC and saline in the short term (D62) (B), while only after 6 months or D182 (long-term) showed the statistical difference between hIDPSC-treated and saline groups (*) (C). Statistical analysis performed through ANOVA, followed by Tukey post hoc test (both with significance level of 5%). p-values < 0.001 (**), or < 0.05 (*) indicate significant differences. p-values > 0.05 indicate absence of significant differences (ns—non-significant). Scale bars = 50 µm (40×).